IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andreas BERGMANN Group Art Unit: 1641 Serial No.: 10/551,298 Examiner: Christine E. Foster Filed: September 23, 2005 For: DETERMINATION OF MIDREGIONAL PROADRENOMEDULLIN PARTIAL PEPTIDE IN BIOLOGICAL FLUIDS FOR DIAGNOSTIC PURPOSES, AND IMMUNOASSAYS FOR CARRYING OUT SUCH A DETERMINATION INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); within three months of the actual filing date of the national phase of a PCT application; OR before the mailing of a first substantive office action (including after filing of an

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

RCE).

 \boxtimes

	is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR	
		\boxtimes	payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).	
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;	
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
		OR a r	notice of allowance under 37 C.F.R. § 1.311;	
	AND	is filed on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).	
Staten	nents U	nder 37	C.F.R. 1.97(e)	
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or	
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.	
Cited	Materia	<u>als</u>		
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).		
		Copies of materials listed but not attached were cited in an international se report dated		
		Not re	equired by 37 CFR § 1.98.	

\boxtimes	Copies of the materials listed are attached (except for the foregoing).			
Non-English	Language References			
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).			
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:			
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family Translation of other relevant information on foreign search report 			
Other Information				
Payment of	Fees Due (If Any):			
-				
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: VOSS-0043

Date: September 29, 2008

AJZ:klb